ClinicalTrials.gg
CompletedNCT00563316Updated Apr 12, 2016Results posted

Effect of Panitumumab on the Pharmacokinetics of Irinotecan

A Phase 1 interventional study of Panitumumab and Irinotecan in Metastatic Colorectal Cancer, sponsored by Amgen. Completed at 12 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-04-12.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies testing panitumumab in Colorectal Neoplasms — 7 open to participants now, 12 under way, 3 of them phase 3. Panitumumab · Colorectal Neoplasms.

Enrollment
67th of 88
28 · median 70
Started
2008
with 5 others
Phase 1
6 of 90
2 open now
Registered
19th of 90
by date
Lead sponsor
20 of 90
Amgen

Among the 90 studies testing panitumumab in Colorectal Neoplasms, this one is the 67th largest by enrollment of the 88 interventional ones that give a count, is one of 6 that started in 2008, is one of 6 in phase 1, and was the 19th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

7 of the 90 studies testing panitumumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About panitumumab

Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing panitumumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The primary objective of this study is to determine if panitumumab affects the pharmacokinetic (PK) profile of irinotecan.

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • colorectal cancer
  • chemotherapy
  • cancer
  • metastatic
  • irinotecan
  • EGFr
  • epidermal growth factor
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed unresectable colorectal cancer (mCRC) which has progressed on at least one prior 5-fluorouracil (5FU)-containing chemotherapy regimen
  • (ECOG) performance status of 0, 1, or 2
  • of ≥ 3 months as documented by the investigator
  • Baseline actual body weight ≤ 160 kg
  • Competent to comprehend, sign, and date a written Institutional Review Board (IRB) approved form before any study-specific procedures are performed

Exclusion criteria

Exclusion Criteria:

  • Treatment with radiotherapy ≤ 14 days before enrollment. Patients must have recovered from all radiotherapy-related toxicities
  • Known presence of central nervous systems (CNS)
  • Any prior (except for non-melanomatous skin cancer or in situ cervical cancer) other than the study disease, unless treated with curative intent with no evidence of disease ≤ 2 years before enrollment
  • History of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest computed tomography (CT) scan
  • Active inflammatory bowel disease or other bowel disease causing chronic diarrhea (defined as > (CTCAE version 3) grade 2
  • cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrollment
  • UGT1A1*28 TA7/7, TA7/8, TA8/8 genetic polymorphisms; Gilbert's Disease
  • Treatment with enzyme inhibiting or inducing medications ≤ 2 weeks before enrollment
  • Prior anti-epidermal growth factor receptor (EGFr) antibody therapy (eg, cetuximab) or treatment with small molecule EGFr inhibitors (eg, gefitinib, erlotinib, lapatinib)
  • Systemic chemotherapy, hormonal therapy, immunotherapy, or experimental or approved proteins/antibodies (eg, bevacizumab) ≤ 30 days before enrollment
  • Subjects requiring agents (eg, methotrexate and cyclosporine), however are allowed
  • Major surgery \< 28 days prior to enrollment or minor surgery (excluding catheter placement) \< 14 days before enrollment
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Panitumumab + Irinotecan

    Participants received panitumumab 6 mg/kg and irinotecan 180 mg/m² administered by intravenous (IV) infusion every 2 weeks until disease progression or intolerance of panitumumab, irinotecan or both.

    Drug: Panitumumab · Drug: Irinotecan

Interventions

  • The first infusion of panitumumab will occur on Cycle 1 Day 4. On Cycle 2 Day 1, panitumumab will be administered on the same day as irinotecan and every 2 weeks thereafter.

    Also known as: Vectibix

  • The first infusion of irinotecan will occur on Cycle 1 Day 1. Irinotecan will be administered on the same day as panitumumab on Cycle 2 Day 1 and every 2 weeks thereafter.

    Also known as: Camptosar

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Irinotecan

    To analyze the effect, if any, that panitumumab had on the pharmacokinetics of irinotecan, the Cmax of irinotecan administered alone (Cycle 1) and with concomitant panitumumab (Cycle 2) was measured. Plasma samples were assayed by a validated high performance liquid chromatography (HPLC)-fluorescence method for the measurement of irinotecan. The lower limit of quantitation (LLOQ) was 2 ng/mL.

    Time frame: Predose and at 10 minutes, and 0.5, 1, 2, 4, 8, 24, 48, and 72 hours after the end of the irinotecan infusion at cycle 1 (irinotecan alone, week 1 day 1) and cycle 2 (irinotecan with panitumumab, week 3, day 1).

  2. Area Under the Plasma Concentration-time Curve From the Time of Dosing to Infinity (AUCinf) for Irinotecan

    To analyze the effect, if any, that panitumumab had on the pharmacokinetics of irinotecan, the AUCinf of irinotecan administered alone (Cycle 1) and with concomitant panitumumab (Cycle 2) was measured.

    Time frame: Predose and at 10 minutes, and 0.5, 1, 2, 4, 8, 24, 48, and 72 hours after the end of the irinotecan infusion at cycle 1 (irinotecan alone, week 1 day 1) and cycle 2 (irinotecan with panitumumab, week 3, day 1).

  3. Area Under the Plasma Concentration-time Curve From the Time of the Last Quantifiable Concentration (AUClast) for Irinotecan

    To analyze the effect, if any, that panitumumab had on the pharmacokinetics of irinotecan, the AUClast of irinotecan administered alone (Cycle 1) and with concomitant panitumumab (Cycle 2) was measured.

    Time frame: Predose and at 10 minutes, and 0.5, 1, 2, 4, 8, 24, 48, and 72 hours after the end of the irinotecan infusion at cycle 1 (irinotecan alone, week 1 day 1) and cycle 2 (irinotecan with panitumumab, week 3, day 1).

  4. Number of Participants With Clinically Significant Adverse Events (AEs)

    Adverse events of special interest include infusion reactions, integument toxicities, diarrhea, stomatitis, hypomagnesemia, and pulmonary, vascular, and cardiac toxicities. Infusion reactions were defined as 1. Prespecified signs and symptoms indicating a possible infusion reaction (derived from Common Terminology Criteria for Adverse Events (CTCAE) definitions of allergic reaction/hypersensitivity and cytokine release syndrome/acute infusion reaction) with onset day coincident with any study drug infusion and which resolved the day of, or the day after, onset; 2. incidence of AE with terms consistent with the panitumumab US package insert (USPI) (any event within 24 hours of an infusion during the clinical study described as allergic reaction or anaphylactoid reaction, or any event occurring on the first day of dosing described as allergic reaction, anaphylactoid reaction, fever, chills, or dyspnea). Data are summarized overall and by treatment phase.

    Time frame: The reporting time frame for Adverse Events is from first dose date to 30 days since the last dose date, until the data cut-off date of 16 July 2009. The median time frame is 5.7 months.

07

Results

Posted Apr 12, 2016

Participant flow

This study was conducted at 6 sites in the United States and Canada. The first patient enrolled on 28 March 2008 and the last patient enrolled on 30 January 2009. Results are reported up until the data cut-off date of 16 July 2009.

Participant flow — Overall Study
MilestonePanitumumab + Irinotecan
Started28
Received investigational product27
Completed16
Not completed12
Withdrew: Adverse event2
Withdrew: Physician decision1
Withdrew: Lost to follow-up2
Withdrew: Death1
Withdrew: On-going in study as of 16 july 2009.5
Withdrew: Other1

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of Irinotecan

To analyze the effect, if any, that panitumumab had on the pharmacokinetics of irinotecan, the Cmax of irinotecan administered alone (Cycle 1) and with concomitant panitumumab (Cycle 2) was measured. Plasma samples were assayed by a validated high performance liquid chromatography (HPLC)-fluorescence method for the measurement of irinotecan. The lower limit of quantitation (LLOQ) was 2 ng/mL.

Time frame:
Predose and at 10 minutes, and 0.5, 1, 2, 4, 8, 24, 48, and 72 hours after the end of the irinotecan infusion at cycle 1 (irinotecan alone, week 1 day 1) and cycle 2 (irinotecan with panitumumab, week 3, day 1).
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Irinotecan
ng/mLPanitumumab + Irinotecan
Cycle 11570 ± 321
Cycle 21570 ± 520
Statistical analysis
  • Panitumumab + Irinotecan · Least squares geometric mean ratio: 0.980 · 90% CI 0.894 to 1.074Ratio of Cycle 2 : Cycle 1
PrimaryArea Under the Plasma Concentration-time Curve From the Time of Dosing to Infinity (AUCinf) for Irinotecan

To analyze the effect, if any, that panitumumab had on the pharmacokinetics of irinotecan, the AUCinf of irinotecan administered alone (Cycle 1) and with concomitant panitumumab (Cycle 2) was measured.

Time frame:
Predose and at 10 minutes, and 0.5, 1, 2, 4, 8, 24, 48, and 72 hours after the end of the irinotecan infusion at cycle 1 (irinotecan alone, week 1 day 1) and cycle 2 (irinotecan with panitumumab, week 3, day 1).
Reported as:
Mean · hr*ng/mL
Area Under the Plasma Concentration-time Curve From the Time of Dosing to Infinity (AUCinf) for Irinotecan
hr*ng/mLPanitumumab + Irinotecan
Cycle 112000 ± 4350
Cycle 210700 ± 3930
Statistical analysis
  • Panitumumab + Irinotecan · Least squares geometric mean ratio: 0.898 · 90% CI 0.819 to 0.985Ratio of Cycle 2 : Cycle 1
PrimaryArea Under the Plasma Concentration-time Curve From the Time of the Last Quantifiable Concentration (AUClast) for Irinotecan

To analyze the effect, if any, that panitumumab had on the pharmacokinetics of irinotecan, the AUClast of irinotecan administered alone (Cycle 1) and with concomitant panitumumab (Cycle 2) was measured.

Time frame:
Predose and at 10 minutes, and 0.5, 1, 2, 4, 8, 24, 48, and 72 hours after the end of the irinotecan infusion at cycle 1 (irinotecan alone, week 1 day 1) and cycle 2 (irinotecan with panitumumab, week 3, day 1).
Reported as:
Mean · hr*ng/mL
Area Under the Plasma Concentration-time Curve From the Time of the Last Quantifiable Concentration (AUClast) for Irinotecan
hr*ng/mLPanitumumab + Irinotecan
Cycle 111900 ± 4290
Cycle 210600 ± 3870
Statistical analysis
  • Panitumumab + Irinotecan · Least squares geometric mean ratio: 0.897 · 90% CI 0.818 to 0.983Ratio of Cycle 2 : Cycle 1
PrimaryNumber of Participants With Clinically Significant Adverse Events (AEs)

Adverse events of special interest include infusion reactions, integument toxicities, diarrhea, stomatitis, hypomagnesemia, and pulmonary, vascular, and cardiac toxicities. Infusion reactions were defined as 1. Prespecified signs and symptoms indicating a possible infusion reaction (derived from Common Terminology Criteria for Adverse Events (CTCAE) definitions of allergic reaction/hypersensitivity and cytokine release syndrome/acute infusion reaction) with onset day coincident with any study drug infusion and which resolved the day of, or the day after, onset; 2. incidence of AE with terms consistent with the panitumumab US package insert (USPI) (any event within 24 hours of an infusion during the clinical study described as allergic reaction or anaphylactoid reaction, or any event occurring on the first day of dosing described as allergic reaction, anaphylactoid reaction, fever, chills, or dyspnea). Data are summarized overall and by treatment phase.

Time frame:
The reporting time frame for Adverse Events is from first dose date to 30 days since the last dose date, until the data cut-off date of 16 July 2009. The median time frame is 5.7 months.
Reported as:
Number · participants
Number of Participants With Clinically Significant Adverse Events (AEs)
participantsPanitumumab + IrinotecanTreatment Phase 1Treatment Phase 2Treatment Phase 3Treatment Phase 4
Any adverse events of Interest27526926
Integument Toxicities25024224
Diarrhea23212420
Hypomagnesemia1301013
Stomatitis/Oral Mucositis130608
Pulmonary Toxicity90417
Infusion Reaction CTCAE82054
Infusion Reaction USPI21001
Vascular Toxicity50203
Neuro Toxicities30111
Cardiac Toxicity21002
Hematological Toxicities20002

Adverse events

Collected over The reporting time frame for Adverse Events is from first dose date to 30 days since the last dose date, until the data cut-off date of 16 July 2009. The median time frame is 5.7 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panitumumab With Irinotecan—4/27 (14.8%)27/27 (100%)
Most frequent serious events
Most frequent serious events
EventPanitumumab With Irinotecan
DehydrationMetabolism and nutrition disorders2/27
DiarrhoeaGastrointestinal disorders1/27
NauseaGastrointestinal disorders1/27
Small intestinal obstructionGastrointestinal disorders1/27
VomitingGastrointestinal disorders1/27
Gait disturbanceGeneral disorders1/27
Bile duct obstructionHepatobiliary disorders1/27
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/27
Deep vein thrombosisVascular disorders1/27
Most frequent other events
Showing 10 of 56
Most frequent other events
EventPanitumumab With Irinotecan
FatigueGeneral disorders25/27
DiarrhoeaGastrointestinal disorders23/27
Dermatitis acneiformSkin and subcutaneous tissue disorders19/27
HypomagnesaemiaMetabolism and nutrition disorders13/27
NauseaGastrointestinal disorders12/27
ConstipationGastrointestinal disorders11/27
Skin fissuresSkin and subcutaneous tissue disorders11/27
ParonychiaInfections and infestations10/27
VomitingGastrointestinal disorders9/27
XerosisGeneral disorders9/27

Baseline characteristics

Safety analysis set (all participants who received at least 1 dose of panitumumab or irinotecan)

Age, Continuous
Age, Continuous(years)Panitumumab + Irinotecan
Mean58.1 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)Panitumumab + Irinotecan
Female9
Male18
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Panitumumab + Irinotecan
White or Caucasian17
Black or African American0
Hispanic or Latino0
Asian8
Japanese1
American Indian or Alaska Native0
Native Hawaiian or Other Pacific Islander0
Aborigine0
Other1
Primary Tumor Type
Primary Tumor Type(participants)Panitumumab + Irinotecan
Colon Cancer17
Rectal Cancer10
08

Study locations

12 sites
  • Research Site
    Billings, Montana 59107, United States
  • Research Site
    Billings, Montana, United States
  • Research Site
    Chapel Hill, North Carolina 27599, United States
  • Research Site
    Chapel Hill, North Carolina, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Philadelphia, Pennsylvania, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Nashville, Tennessee, United States
  • Research Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Research Site
    Vancouver, British Columbia, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Toronto, Ontario, Canada
09

References and documents

Publications

  • Yang BB, Wu CY, Chen E, Infante JR, Chen A, Gao B, Smith B, Litten J, Kennecke H. Pharmacokinetics of Irinotecan With and Without Panitumumab Coadministration in Patients With Metastatic Colorectal Cancer. Clin Pharmacol Drug Dev. 2013 Jul;2(3):205-12. doi: 10.1002/cpdd.35. Epub 2013 May 15. PubMed 27121781 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Mar 2009 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 7 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2007
First posted
Nov 26, 2007
Start
Mar 2008
Primary completionActual
Mar 2009
CompletionActual
Jun 2010
Results first posted
Apr 12, 2016
Last update
Apr 12, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00563316
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Nov 26, 2007
Start date
Mar 2008
Primary completion
Mar 2009
Completion
Jun 2010
Results posted
Apr 12, 2016
Last update
Apr 12, 2016

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Panitumumab · Irinotecan

Start the discussion